Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease | Zendy

Sabina A. Murphy | Zendy; Terje R. Pedersen | Zendy; Zbigniew Gaciong | Zendy; R Češka | Zendy; М. В. Ежов | Zendy; Derek Connolly | Zendy; J. Wouter Jukema | Zendy; Kálmán Tóth | Zendy; Matti J. Tikkanen | Zendy; Canqing Yu | Zendy; Stephen D. Wiviott | Zendy; Christopher E. Kurtz | Zendy; Narimon Honarpour | Zendy; Robert P. Giugliano | Zendy; Anthony Keech | Zendy; Peter Sever | Zendy; Marc S. Sabatine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease

Author(s) -

Sabina A. Murphy,

Terje R. Pedersen,

Zbigniew Gaciong,

R Češka,

М. В. Ежов,

Derek Connolly,

J. Wouter Jukema,

Kálmán Tóth,

Matti J. Tikkanen,

Canqing Yu,

Stephen D. Wiviott,

Christopher E. Kurtz,

Narimon Honarpour,

Robert P. Giugliano,

Anthony Keech,

Peter Sever,

Marc S. Sabatine

Publication year - 2019

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2019.0886

Subject(s) - medicine , evolocumab , pcsk9 , hazard ratio , clinical endpoint , alirocumab , myocardial infarction , unstable angina , cardiology , placebo , stroke (engine) , discontinuation , statin , surrogate endpoint , clinical trial , cholesterol , confidence interval , lipoprotein , mechanical engineering , ldl receptor , alternative medicine , apolipoprotein a1 , pathology , engineering

The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurrent cardiovascular events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research